Arno Therapeutics, a clinical-stage company focused on developing products for the treatment of cancer, today announced that its investigational compound AR-42 has been granted orphan-drug designation by the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products for the treatment of neurofibromatosis type 2 (NF2), a rare genetic disorder characterized by the growth of noncancerous tumors in the brain and spinal cord, juvenile cataracts, and neurofibromas of the skin.
The EMA grants orphan-drug designation for medicines designed to treat life-threatening or debilitating conditions affecting no more than five in 10,000 people, and allows the developer to obtain inspection-fee reductions, protocol assistance, a centralized application procedure, and 10 years of marketing exclusivity when/if the drug is approved.
“The EMA’s orphan-drug designation represents another important step in our development program for AR-42 that will help us pursue its clinical development for the treatment in this rare and debilitating disease,” Glenn Mattes, president and CEO of Arno stated in the press release.
AR-42 is currently being studied in a phase I/IIa clinical trial in adult patients with relapsed or refractory hematologic malignancies and solid tumors.
The U.S. FDA has also awarded EMA, AR-42 orphan drug designation for the treatment of meningioma and schwannoma of the central nervous system, and is currently reviewing the candidate for U.S. orphan-drug designation for the treatment of neurofibromatosis type 2-associated central nervous system tumors.
For more information visit www.atnothera.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment